Alpha-1 antitrypsin deficiency
Natural Standard Monograph, Copyright © 2013 (www.naturalstandard.com). Commercial distribution prohibited. This monograph is intended for informational purposes only, and should not be interpreted as specific medical advice. You should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.
AAT, AAT deficiency, AATD, alpha-1 antitrypsin, alpha-1 related emphysema, emphysema, inherited emphysema, liver disease, lung disease, neutrophil elastase, respiratory defects.
Alpha-1 antitrypsin deficiency is an inherited genetic disease in which tissue in the liver or lungs may become damaged, which prevents them from working properly. The first symptoms of alpha-1 antitrypsin deficiency usually occur between the ages of 20 and 50, but some infants or children may be affected with the disease as well. About one in 3,000 to 5,000 people are affected with alpha-1 antitrypsin deficiency.
Alpha-1 antitrypsin deficiency results from a genetic mutation that causes the body to make reduced levels or an abnormal form of a protein called alpha-1 antitrypsin. Alpha-1 antitrypsin normally protects the body from a powerful enzyme made by white blood cells. In patients with alpha-1 antitrypsin deficiency, this enzyme is not properly controlled, and it can damage the lungs.
Individuals with alpha-1 antitrypsin deficiency usually experience respiratory symptoms, including shortness of breath following mild activity, reduced ability to exercise, wheezing, coughing, recurring respiratory infections, fatigue, and rapid heartbeat upon standing. Eventually, patients may develop emphysema, a condition in which the small air sacs in the lungs (called alveoli) become damaged. Patients with emphysema experience difficulty breathing, a hacking cough, and may develop a barrel shaped chest. The respiratory symptoms patients develop result from tissue damage in the lungs.
Some patients with alpha-1 antitrypsin deficiency may develop liver disease and experience symptoms such as a swollen abdomen, swollen feet or legs, and yellowing of the skin and whites of the eyes.
Currently there is no known way to prevent alpha-1 antitrypsin deficiency. Patients with alpha-1 antitrypsin deficiency may have reduced life expectancies, depending on the severity of the symptoms.
Alpha-1 antitrypsin deficiency is known to result from inheriting a mutated form of the SERPINA1 gene. SERPINA1 makes a protein that normally protects the body from a powerful enzyme made by white blood cells called neutrophil elastase. Individuals normally have two copies of the SERPINA1 gene. An individual with just one mutated copy of SERPINA1 has a low likelihood of developing alpha-1 antitrypsin deficiency, but an individual carrying two mutated copies of SERPINA1 is likely to develop the disease. Therefore, couples in which each parent has a mutated SERPINA1 gene are at a greater risk of having a child affected with alpha-1 antitrypsin deficiency, as each parent could pass a mutated copy of SERPINA1 to the child.
Some mutations in the SERPINA1 gene are not as severe as others and only slightly reduce the ability of the gene to function properly. Individuals carrying these less severe mutated forms of SERPINA1 have a lower risk of passing the disease to children.
Alpha-1 antitrypsin deficiency results from a mutation in a gene called SERPINA1. This mutation causes the body to make reduced levels or an abnormal form of a protein called alpha-1 antritrypsin.
Alpha-1 antitrypsin normally protects the body from a powerful enzyme made by white blood cells called neutrophil elastase. The normal function of neutrophil elastase is to fight infections. However, in patients with alpha-1 antitrypsin deficiency, neutrophil elastase is not properly controlled and it can damage the lungs.
If abnormal alpha-1 antitrypsin protein is made by the body as a result of a mutation, it may accumulate in the liver, causing liver disease.
Signs and Symptoms
Respiratory problems: Individuals with alpha-1 antitrypsin deficiency usually experience respiratory symptoms, including shortness of breath following mild activity, reduced ability to exercise, coughing, wheezing, recurring respiratory infections, fatigue, and rapid heartbeat upon standing. Patients may also spit up mucus from the respiratory tract.
Liver problems: About 10% to 15% of patients with alpha-1 antitrypsin deficiency develop liver disease, with symptoms including a swollen abdomen, swollen feet or legs, and yellowing of the skin and whites of the eyes. Scarring of the liver, called cirrhosis, may also occur.
Alpha-1 antitrypsin deficiency may be difficult to diagnose, because no single physical sign or symptom can be used to confirm a diagnosis. Genetic testing and blood tests may provide a more conclusive diagnosis.
Clinical exam: A clinical examination of the respiratory system and chest, either with X-rays or by listening for abnormal sounds with a stethoscope, may help identify respiratory abnormalities in patients. Checking for the various respiratory symptoms associated with the disease can help in making a diagnosis. Physicians can also look for signs of increased respiratory work or airflow obstruction.
Genetic tests: Mutations in the SERPINA1 gene are known to cause alpha-1 antitrypsin deficiency. Genetic tests can be used to check for these mutations and diagnose alpha-1 antitrypsin deficiency.
Blood tests: Tests can be performed to measure the level of alpha-1 antitrypsin in a patient's blood. Low levels may indicate that the patient is affected with alpha-1 antitrypsin deficiency.
Panniculitis: A small number of patients with alpha-1 antitrypsin deficiency may develop panniculitis, a condition in which the skin becomes hardened and painful lumps and patches appear.
Emphysema: Patients may develop emphysema, a condition in which the small air sacs in the lungs (called alveoli) become damaged. Patients with emphysema experience difficulty breathing, a hacking cough, and a barrel shaped chest.
Airway problems: Alpha-1 antitrypsin deficiency may lead to a number of other respiratory problems, including chronic bronchitis (an inflammation of the airways of the lungs) and bronchiectasis (an irreversible dilation of some airways in the lungs). Infection of the upper respiratory tract may be observed in some patients.
Emphysema and cirrhosis of the liver are both life-threatening conditions and may contribute to death in patients with alpha-1 antitrypsin deficiency. However, not all patients with alpha-1 antitrypsin deficiency develop these severe complications.
Alpha-1 antitrypsin normally protects the body from a powerful enzyme made by white blood cells, called neutrophil elastase. The normal function of neutrophil elastase is to fight infections. However, in patients with alpha-1 antitrypsin deficiency, neutrophil elastase is not properly controlled and it can damage the lungs.
Liver disease: If abnormal alpha-1 antitrypsin protein is made by the body as a result of a mutation, it may accumulate in the liver, causing liver disease.
Currently, there is no known cure for alpha-1 antitrypsin deficiency. A number of treatments exist to help patients manage symptoms of this disorder.
Alpha-1 antitrypsin protein: Alpha-1 antitrypsin deficiency may be treated with alpha-1 antitrypsin protein obtained from the blood of healthy individuals. If normal alpha-1 antitrypsin protein is delivered intravenously to patients, it may slow the course of the disease and prevent further damage to the lungs.
Transplantation: If liver disease becomes severe, a liver transplantation may be necessary. Lung transplantation may be necessary in cases where the lungs become severely damaged.
Avoid irritants: Patients with alpha-1 antitrypsin deficiency should avoid smoking. Smoking may accelerate the rate at which a patient's lungs become damaged. Also, avoiding dust, fumes, and other environmental irritants is recommended.
Antibiotics: Antibiotics are available that can be used to treat respiratory tract infections.
Bronchodilators: Bronchodilators, which are medicines that can be used to dilate the airways, may help patients who have difficulty breathing. The beta-agonist family of bronchodilators, which cause the bronchial muscles to relax, may be used to treat alpha-1 antitrypsin deficiency. Side effects of beta-agonist bronchodilators include jitteriness, heart pounding, and a nervous feeling.
Currently, there is a lack of scientific data on the use of integrative therapies for the treatment or prevention of alpha-1 antitrypsin deficiency.
There are currently no known ways to prevent alpha-1 antitrypsin deficiency.
This information has been edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).
Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Alpha-1 Association. www.alpha1.org
DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004 Mar;59(3):259-64. View Abstract
Dowson LJ, Guest PJ, and Stockley RA. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (PiZ). Chest. 2002 Oct;122(4):1247-55. View Abstract
Genetics Home Reference. ghr.nlm.nih.gov
National Library of Medicine. www.nlm.nih.gov
Natural Standard: The Authority on Integrative Medicine. www.naturalstandard.com.
Snyder MR, Katzmann JA, Butz ML, et al. Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. Clin Chem. 2006 Dec;52(12):2236-42. View Abstract
Soy D, de la Roza C, Lara B, et al. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax. 2006 Dec;61(12):1059-64. View Abstract
Stoller JK. Key current clinical issues in alpha-1 antitrypsin deficiency. Respir Care. 2003 Dec;48(12):1216-21. View Abstract
Copyright © 2013 Natural Standard (www.naturalstandard.com)
The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.
March 22, 2017